Loading
A phase 1/2 trial of Azacitidine in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies is a phase 1/2 interventional study registered as NCT07011186 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 138 participants planned, started 2024-04-17 and due to reach its primary completion in 2025-10. Interventions recorded: TQB3909 Tablets + Azacitidine.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.